PubMedCrossRef 18. Dal Sasso M, Culici M, Bovio C, Braga PC: Gemifloxacin: effects of sub-inhibitory concentrations on various factors affecting bacterial virulence. Int J Selleck AZD9291 Antimicrob Agents 2003, 21:325–333.PubMedCrossRef 19. Dorman CJ, Ni Bhriain N, Higgins CF: DNA supercoiling and environmental regulation of virulence gene expression in Shigella flexneri . Nature 1990, 344:789–792.PubMedCrossRef 20. Mesak LR, Davies J: Phenotypic changes in ciprofloxacin-resistant Staphylococcus aureus . Res Microbiol 2009,

160:785–791.PubMedCrossRef 21. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K: A large outbreak of Selleckchem FK866 Clostridium difficile -associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273–280.PubMedCrossRef 22. Noren T: Clostridium difficile and the disease it causes. Methods Mol Biol 2010, 646:9–35.PubMedCrossRef 23. Pawlowski SW, Archbald-Pannone L, Carman RJ, Alcantara-Warren C, Lyerly D, Genheimer CW:

Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile . J Hosp Infect 2009, 73:185–187.PubMedCrossRef 24. Saxton K, Baines SD, Freeman J, O’Connor R, Wilcox MH: Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob Agents Chemother 2009, 53:412–420.PubMedCrossRef 25. Uchida JPH203 Y, Mochimaru T, Morokuma Y, Kiyosuke M, Fujise M, Eto F: Clonal spread in Eastern Asia of ciprofloxacin-resistant Escherichia coli serogroup O25 strains, and associated virulence factors. Int J Antimicrob Agents 2010, 35:444–450.PubMedCrossRef 26. Drews SJ, Poutanen SM, Mazzulli T, McGeer AJ, Sarabia A, Pong-Porter S: Decreased prevalence of virulence factors among ciprofloxacin-resistant uropathogenic Escherichia coli isolates. J Clin Microbiol 2005, 43:4218–4220.PubMedCrossRef 27. Ferjani S, Saidani M, Ennigrou S, Hsairi M, Ben Redjeb S: Virulence determinants, phylogenetic groups and fluoroquinolone resistance in Escherichia coli isolated from cystitis and pyelonephritis. Pathol

Biol (Paris) 2012, 60:270–274.CrossRef 28. Sun J, Hu J, Peng H, Shi J, Dong Z: Molecular and physiological characterization Obatoclax Mesylate (GX15-070) of fluoroquinolone resistance in relation to uropathogenicity among Escherichia coli isolates isolated from Wenyu River, China. Chemosphere 2012, 87:37–42.PubMedCrossRef 29. Rafii F, Park M, Novak JS: Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones. Antimicrob Agents Chemother 2005, 49:488–492.PubMedCrossRef 30. Rafii F, Park M, Bryant AE, Johnson SJ, Wagner RD: Enhanced production of phospholipase C and perfringolysin O (alpha and theta toxins) in a gatifloxacin-resistant strain of Clostridium perfringens . Antimicrob Agents Chemother 2008, 52:895–900.PubMedCrossRef 31.